Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,963 | 0,995 | 17:14 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
27.05. | Cereno Scientific - Firing on all cylinders | 247 | Edison Investment Research | In Q125, Cereno made tangible progress across both its clinical programmes. The period opened with new data for lead asset CS1 indicating disease-modifying signals, and was capped by FDA endorsement... ► Artikel lesen | |
CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
27.05. | Cereno Scientific is nominated and shortlisted for 'Company of the Year' in the European Mediscience Awards 2025 | 1 | Cision News | ||
23.05. | Cereno Scientific AB: Cereno Scientific receives endorsement from FDA on plans for Phase IIb trial of CS1 in rare disease pulmonary arterial hypertension (PAH) | 97 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
22.05. | Cereno Scientific AB: Cereno Scientific publishes Interim Report for Q1 2025 (January 1 - March 31, 2025) | 138 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
15.05. | Cereno Scientific publishes Annual Report for 2024 | 1 | Cision News | ||
13.05. | Cereno Scientific presented CS1's Phase IIa trial results at the 5th Baltic Pulmonary Hypertension Conference 2025 | 2 | Cision News | ||
09.05. | Cereno Scientific give notice to attend the Annual General Meeting 2025 | 1 | Cision News | ||
07.05. | Correction: Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on June 10, 2025 | 1 | Cision News | ||
07.05. | Cereno Scientific's Nomination Committee proposes new Board with M&A profile ahead of the Annual General Meeting on May 10, 2025 | 2 | Cision News | ||
07.05. | Cereno Scientific to present at ABGSC Investor Days on May 13-14, 2025, in Stockholm | 1 | Cision News | ||
23.04. | Cereno Scientific - CS1 takes another step towards Phase IIb | 267 | Edison Investment Research | Cereno Scientific has successfully completed its planned Type C meeting with the FDA for lead asset CS1. The minutes from the meeting will be available after 30 days, but Cereno has indicated that the... ► Artikel lesen | |
22.04. | Cereno Scientific aligns with FDA on CS1 development | 3 | Cision News | ||
22.04. | Cereno Scientific AB: Cereno Scientific completes successful FDA meeting discussing further clinical development of drug candidate CS1 in rare disease PAH | 160 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
17.04. | Cereno Scientific - CS014 completes Phase I, path clears for Phase II | 327 | Edison Investment Research | Cereno Scientific has announced that its second clinical stage asset, CS014, has completed the Phase I safety study, with the conclusion of the second, multiple ascending dose (MAD) part of the trial... ► Artikel lesen | |
16.04. | CERENO SCIENTIFIC: Cereno completes CS014 trial ahead of June top-line data | 1 | Cision News | ||
16.04. | Cereno Scientific AB: Cereno Scientific reports that its Phase I trial of CS014 has been concluded and confirms that top-line results are anticipated in June 2025 | 119 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
14.04. | Cereno Scientific to attend BIO International Convention 2025 - largest and most comprehensive event for biotechnology | 1 | Cision News | ||
17.03. | Cereno Scientific AB: Cereno Scientific extends patent protection for drug candidate CS1 in the US and has filed to extend market exclusivity to 2045 | 288 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
12.03. | Cereno Scientific secures FDA meeting to advance its development of CS1 for the treatment of rare disease PAH | 3 | Cision News | ||
28.02. | Cereno Scientific shares invitation to the webcast for the CS1 Phase IIa trial data presentation at 14:00 CET on March 4 | 1 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 40,135 | -0,36 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
BIONTECH | 96,45 | +0,21 % | Allianz gegen Krebs: BioNTech sichert sich Milliarden-Deal mit Bristol Myers: Aktie explodiert! | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech erhält 1,5 Milliarden US-Dollar Vorschuss von Bristol Myers - für die gemeinsame Entwicklung eines vielversprechenden Krebswirkstoffs.... ► Artikel lesen | |
EVOTEC | 7,004 | +0,14 % | DAX nach Feiertag wieder bei 24.000 - Douglas, Evotec, Fresenius, Merck, Renk und SAP im Check | An Christi Himmelfahrt hat es am deutschen Aktienmarkt bei dünnen Umsätzen etwas an Boden verloren. Die Verluste macht der DAX aber am letzten Handelstag im Mai schon wieder gut, wobei die Zollpolitik... ► Artikel lesen | |
MODERNA | 23,585 | +0,15 % | Allianz, Amazon, Deutsche Konsum, Gerresheimer, Hensoldt, Moderna - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 46,780 | -0,02 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics erhält positive CHMP-Stellungnahme für Mirdametinib zur Behandlung erwachsener und pädiatrischer Patienten mit NF1-PN | - im Falle einer Marktzulassung wäre Mirdametinib die erste und einzige Behandlung in der Europäischen Union für Erwachsene und Kinder mit NF1-PN -
- die Entscheidung der Europäischen Kommission... ► Artikel lesen | |
VERA THERAPEUTICS | 20,720 | -32,22 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,890 | +5,93 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,170 | +13,01 % | Recursion Pharmaceuticals: MIT and Recursion Release Boltz-2: Next Generation AI Model to Predict Binding Affinity at Unprecedented Speed, Scale, and Accuracy | ||
BEAM THERAPEUTICS | 18,180 | +6,94 % | Beam Therapeutics Announces Orphan Drug Designation For BEAM-101 | WASHINGTON (dpa-AFX) - Beam Therapeutics (BEAM) announced that the FDA has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment... ► Artikel lesen | |
HEIDELBERG PHARMA | 4,700 | +4,44 % | Vorstands-Interview Exklusiv: Heidelberg Pharma - "Unsere innovative Krebstherapie ist angetreten, um Resistenzen zu überwinden" | Heidelberg Pharma hat sich mit einer klaren Mission dem Kampf gegen Krebs verschrieben: Therapien zu entwickeln, die wirksam, verträglich und vor allem eins können - Resistenzen überwinden. Mit einem... ► Artikel lesen | |
CUREVAC | 3,856 | -1,23 % | Kauf-Alarm bei CureVac: Insider decken sich massenhaft mit Aktien ein - Das müssen Sie jetzt beachten! | ||
MOONLAKE IMMUNOTHERAPEUTICS | 48,030 | -1,72 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
BB BIOTECH | 32,800 | 0,00 % | BB Biotech - Optimistic about biotech's long-term prospects | During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution... ► Artikel lesen | |
KINIKSA PHARMACEUTICALS | 29,850 | +1,08 % | Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | - KPL-387 Phase 2/3 trial on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 -- KPL-387 Phase 1 single ascending dose data support profile for monthly dosing -- Presentation and webcast... ► Artikel lesen | |
KYMERA THERAPEUTICS | 48,670 | +2,10 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Phase 1 healthy volunteer data of KT-621, a once-a-day STAT6 degrader, surpass Kymera's target product profile, significantly derisking program and further validating its oral, biologics-like profile... ► Artikel lesen |